NVO - Novo Nordisk A/S - Stock Price & Dividends

Novo Nordisk A/S is a global healthcare company that specializes in the development, manufacturing, and distribution of pharmaceutical products, with a strong focus on diabetes and obesity care, as well as rare diseases.

The company operates through two main segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a range of products for the treatment of diabetes, obesity, and related cardiovascular conditions, as well as emerging therapy areas such as non-alcoholic steatohepatitis (NASH) and chronic kidney disease.

The Rare Disease segment provides products for the treatment of rare blood disorders, such as hemophilia and von Willebrand disease, as well as rare endocrine disorders, including growth hormone deficiency and Turner syndrome. Additionally, the company offers hormone replacement therapy products for the treatment of conditions such as hypogonadism and growth hormone deficiency.

Novo Nordisk A/S is also a leading manufacturer of insulin pens, growth hormone pens, and injection needles, which are designed to make it easier for patients to self-administer their medications. Furthermore, the company has developed smart solutions for diabetes treatment, including smart insulin pens and the Dose Check app, which helps patients track their insulin doses and adjust their treatment plans accordingly.

In addition to its own research and development efforts, Novo Nordisk A/S collaborates with other companies to expand its product portfolio. For example, the company has a partnership with Aspen Pharmaceuticals to produce insulin products, which helps to increase access to affordable insulin for patients around the world.

Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark, and has a global presence with operations in over 80 countries. The company is committed to improving the lives of people with chronic diseases, and its products are used by millions of patients worldwide.